Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics

Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin–based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipop...

Descripción completa

Detalles Bibliográficos
Autores principales: Landray, M.J., REVEAL Collaborative Group
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mosby 2017
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419667/
https://www.ncbi.nlm.nih.gov/pubmed/28454801
http://dx.doi.org/10.1016/j.ahj.2017.02.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419667/
https://www.ncbi.nlm.nih.gov/pubmed/28454801
http://dx.doi.org/10.1016/j.ahj.2017.02.021

Ejemplares similares